title: Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.
abstract: OBJECTIVE
  To investigate the pharmacokinetic and pharmacodynamic profile of midazolam administered as a concentrated intranasal spray, compared with intravenous midazolam, in healthy adult subjects.
  
  
  METHODS
  Subjects were administered single doses of 5 mg midazolam intranasally and intravenously in a cross-over design with washout period of 1 week. The total plasma concentrations of midazolam and the metabolite 1-hydroxymidazolam after both intranasal and intravenous administration were described with a single pharmacokinetic model. beta-band EEG activity was recorded and related to midazolam plasma concentrations using an exponential pharmacokinetic/pharmacodynamic model.
  
  
  RESULTS
  Administration of the intranasal spray led to some degree of temporary irritation in all six subjects, who nevertheless found intranasal administration acceptable and not painful. The mean (+/-s.d.) peak plasma concentration of midazolam of 71 (+/-25 ng ml-1) was reached after 14 (+/-5 min). Mean bioavailability following intranasal administration was 0.83+/-0.19. After intravenous and intranasal administration, the pharmacokinetic estimates of midazolam were: mean volume of distribution at steady state 1.11+/-0.25 l kg-1, mean systemic clearance 16.1+/-4.1 ml min-1 kg-1 and harmonic mean initial and terminal half lives 8.4+/-2.4 and 79+/-30 min, respectively. Formation of the 1-hydroxymetabolite after intranasal administration did not exceed that after intravenous administration.
  
  
  CONCLUSIONS
  In this study in healthy volunteers a concentrated midazolam nasal spray was easily administered and well tolerated. No serious complications of the mode of administration or the drug itself were reported. Rapid uptake and high bioavailability were demonstrated. The potential of midazolam given via a nasal spray in the acute treatment of status epilepticus and other seizure disruptions should be evaluated.
authors: Stichting Apotheek der Haarlemse Ziekenhuizen (hospital pharmacy), Boerhaavelaan 24, The Netherlands. p.knoester@klinfarm@azn.nl
authors: P D
authors: PD
authors: Knoester
authors: D M
authors: DM
authors: Jonker
authors: R T M
authors: RT
authors: Van Der Hoeven
authors: T A C
authors: TA
authors: Vermeij
authors: P M
authors: PM
authors: Edelbroek
authors: G J
authors: GJ
authors: Brekelmans
authors: G J
authors: GJ
authors: de Haan
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D001682:Biological Availability; D018592:Cross-Over Studies; D005260:Female; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008874:Midazolam / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics*; D008875:Middle Aged; D008954:Models, Biological; D009297:Nasal Mucosa / Q000378:metabolism
chemical_list: D014151:Anti-Anxiety Agents; C040081:1-hydroxymethylmidazolam; D008874:Midazolam